Scarica l'app Stockscreener
1.26
1.59%
-0.00
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BCLI Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$1.26
Aprire:
$1.27
Volume 24 ore:
63,646
Relative Volume:
0.90
Capitalizzazione di mercato:
$6.75M
Reddito:
-
Utile/perdita netta:
$-16.63M
Rapporto P/E:
-2.1356
EPS:
-0.59
Flusso di cassa netto:
$-21.84M
1 W Prestazione:
+9.73%
1M Prestazione:
-43.38%
6M Prestazione:
-86.67%
1 anno Prestazione:
-62.39%
Intervallo 1D:
$1.21
$1.29
Intervallo di 1 settimana:
$1.06
$1.30
Portata 52W:
$1.05
$11.89
Brainstorm Cell Therapeutics Inc Stock (BCLI) Company Profile
Nome
Brainstorm Cell Therapeutics Inc
Settore
Industria
Telefono
201-488-0460
Indirizzo
1325 AVENUE OF AMERICAS, NEW YORK, NY
Confronta BCLI con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| BCLI | 1.24 | 6.75M | 0 | -16.63M | -21.84M | -0.59 |
| VRTX | 449.85 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 747.37 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 600.46 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 247.07 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 108.15 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Brainstorm Cell Therapeutics Inc Stock (BCLI) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2021-02-04 | Aggiornamento | Maxim Group | Hold → Buy |
| 2020-11-17 | Downgrade | Maxim Group | Buy → Hold |
| 2016-12-19 | Reiterato | Maxim Group | Buy |
| 2015-12-22 | Reiterato | Maxim Group | Buy |
Brainstorm Cell Therapeutics Inc Borsa (BCLI) Ultime notizie
Stem Cell Therapy Market to Reach $19.1 Billion by 2031 | Advanced - openPR
Brainstorm Cell Therapeutics Inc. (BCLI) Quarterly 10-Q Report - Quartz
ARMISTICE CAPITAL, LLC Expands Stake in Brainstorm Cell Therapeu - GuruFocus.com
BrainStorm Cell Reports $2.7M Loss, Plans Phase 3b ALS Trial Despite Low Cash | BCLI Stock News - StockTitan
75+ Key Companies Charting New Frontiers in Multiple Sclerosis Therapeutic Space | DelveInsight - The Malaysian Reserve
BrainStorm Cell Therapeutics and Pluri Partner to Support NurOwn® Phase 3b Trial Manufacturing - PR Newswire
Amyotrophic Lateral Sclerosis Market Opportunities, - openPR
BrainStorm Teams with Pluri for Key NurOwn ALS Trial Manufacturing Partnership | BCLI Stock News - StockTitan
Amyotrophic Lateral Sclerosis Treatment Market to Grow by USD 663.7 Million from 2024-2028, as Rising Incidence Drives Demand with AI Redefining Market LandscapeTechnavio - The Malaysian Reserve
BrainStorm regains Nasdaq compliance with bid price rule By Investing.com - Investing.com South Africa
BrainStorm regains Nasdaq compliance with bid price rule - Investing.com India
BrainStorm Cell Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement - PR Newswire
Neuromuscular Disease Therapeutics Market Statistical - openPR
BrainStorm Cell Therapeutics Presented Positive Survival Data from NurOwn® Expanded Access Program at 2024 Annual NEALS Meeting - PR Newswire
Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Short Interest Update - MarketBeat
Brainstorm Cell Therapeutics (NASDAQ:BCLI) Shares Cross Above 200-Day Moving AverageShould You Sell? - MarketBeat
Amyotrophic Lateral Sclerosis (ALS) Market: Detailed Analysis - openPR
ROSEN, NATIONAL TRIAL LAWYERS, Encourages Brainstorm Cell Therapeutics Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the FirmBCLI - AsiaOne
Stem Cell Therapy Market Projected to Reach $831.9 Million By 2032 - 대구포스트
Short Interest in Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Declines By 91.1% - MarketBeat
Autologous Stem Cell and Non-Stem Cell Based Therapies Industry Report By Type, Application and Geography - Elektrotransports.lv
Brainstorm Cell Therapeutics (NASDAQ:BCLI) Coverage Initiated at StockNews.com - MarketBeat
BCLIBrainstorm Cell Therapeutics Inc. Latest Stock News & Market Updates - StockTitan
BrainStorm Cell Therapeutics to Provide Corporate Update on Phase 3b NurOwn® Trial at the 2024 Maxim Healthcare Virtual Summit - StockTitan
Gene and Cell Therapies for CNS Disorders Market to Experience - openPR
Brainstorm cell therapeutics CEO acquires $11,308 in stock By Investing.com - Investing.com Canada
Brainstorm cell therapeutics CEO acquires $11,308 in stock - Investing.com
Brainstorm Therapeutics Advances NurOwn® Phase 3b Trials - TipRanks
Brainstorm Cell Therapeutics, Inc. (BCLI) requires closer examination - US Post News
5 Best Stem Cell Companies to Invest In (November 2024) - Securities.io
Brainstorm Cell Therapeutics (NASDAQ:BCLI) Research Coverage Started at StockNews.com - Defense World
Market Momentum: Brainstorm Cell Therapeutics, Inc. (BCLI) Registers a -12.57 Decrease, Closing at 0.22 - The Dwinnex
Brainstorm Cell Therapeutics, Inc. (BCLI) Stock: A Year of Market Fluctuations - The InvestChronicle
The Potential Rise in the Price of Brainstorm Cell Therapeutics, Inc. (BCLI) following insiders activity - Knox Daily
Cell Therapy Technologies Market Size, Product Trends, Key Drivers, Share Analysis And Forecast To 2033 - WhaTech
Brainstorm Cell Therapeutics Stock Scheduled to Reverse Split on Tuesday, October 1st (NASDAQ:BCLI) - Defense World
Cell Theraputics Industry Analysis by Regions, Types and Application - Elektrotransports.lv
BrainStorm announces reverse stock split - Investing.com
Stem Cell Therapy Market Growth, Size, Research Report and Forecast (2024-2034) - 대구포스트
BrainStorm Cell Therapeutics Announces Presentations on NurOwn® at 2024 Annual NEALS Meeting - PR Newswire
Global Stem Cell Therapy Market Set to Reach $ 831.9 Million by 2032 with a 17.2% CAGR GrowthGlobal Stem Cell Therapy Market Set to Reach $ 831.9 Million by 2032 with a 17.2% CAGR Growth - 대구포스트
Brainstorm Cell Therapeutics (NASDAQ:BCLI) Now Covered by Analysts at StockNews.com - Defense World
Cell Theraputics Market 2024-2032 Analysis - Economica
Balance Sheet Insights: Brainstorm Cell Therapeutics, Inc. (BCLI)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
BCLI’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - The InvestChronicle
SEC Form S-3 filed by Brainstorm Cell Therapeutics Inc. - Quantisnow
Brainstorm Cell Therapeutics expands stock incentive plans - Investing.com India
Brainstorm Cell Therapeutics expands stock incentive plans By Investing.com - Investing.com Canada
Brainstorm Cell Therapeutics Enacts Key Corporate Changes - TipRanks
Brainstorm Cell Therapeutics Inc Azioni (BCLI) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Brainstorm Cell Therapeutics Inc Azioni (BCLI) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Lebovits Chaim | President & CEO |
Sep 30 '24 |
Buy |
0.23 |
22,000 |
5,016 |
1,186,865 |
| Dagher Ibrahim B. | Chief Medical Officer |
Jul 19 '24 |
Sale |
0.35 |
63,000 |
22,069 |
0 |
1.80%
0.42%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):